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Background: Despite considerable global investigation over several decades, the roles of vitamin D in health and
disease development remains convoluted. One recognised issue is the difficulty of accurately measuring the active
forms of vitamin D. Advances made include some new methods addressing the potential interference by excluding
epimers and isobars. However, there is no evidence that epimers are without function. Therefore, the aim of this
study was to develop and validate, for the first time, a new assay to simultaneously measure levels of six forms of
vitamin D along with two epimers. The assay was applied to multilevel certified reference material (CRM) and 25
pooled human sera samples, obtained from the Vitamin D External Quality Assessment Scheme (DEQAS), to
demonstrate its efficiency.
Results: The assay is capable of simultaneously measuring eight vitamin D analogues over the calibration ranges
and LODs (in nmol/L) of: 1α25(OH)2D2 [0.015-1; 0.01], 1α25(OH)2D3 [0.1-100; 0.01], 25OHD3 [0.5-100, 0.025],
3-epi-25OHD3 [0.1-100, 0.05], 25OHD2 [0.5-100, 0.025], 3-epi-25OHD2 [0.1-100, 0.05], vitamin D3 [0.5-100, 0.05] and
vitamin D2 [0.5-100, 0.05], using stanozolol-d3 as internal standard. Certified reference material and external quality
control samples (DEQAS) were analysed to meet the standards outlined by National Institute of Standards and
Technology (NIST). Validation steps included recovery and both precision and accuracy under inter- and intra-day
variation limit of detection, and analysis of each analyte over a linear range. All validation parameters were in line
with acceptable Food and Drug Administration (FDA) guidelines. All eight analogues were quantified with the
25OHD levels being commensurate with DEQAS data.
Conclusions: This report details the application of a new LC-MS/MS based assay for the efficient analysis of eight
analogues of vitamin D over a range of samples, which is a significant advance over the existing methods.
Simultaneous measure of eight vitamin D analogues does not compromise the analytical capability of the assay to
quantify the commonly used biomarker (25OHD) for vitamin D status. The results demonstrate the feasibility of
applying the assay in research and clinical practice that i) excludes misleading measures owing to epimers and
isobars and ii) is able to quantify the excluded component to facilitate further in vivo investigation into the roles
of ubiquitous epimers.
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Many studies have demonstrated that hypovitaminosis D
is widespread through the Western world leading to pos-
tulations that it is associated with the development and/
or progression of a number of conditions ranging from
neurological disorders through to hypertension, type 1
diabetes, kidney disease and cystic fibrosis [1]. In conse-
quence, many supplemental studies have been con-
ducted with very few successfully altering disease
outcomes [1]. Beyond rickets disease, clinical research
on the putative roles of vitamin D in health and disease
has proven difficult for a number of reasons including: i)
the vitamin exists in multiple forms that are not facile to
measure accurately, with considerable questions about
several methods [2], ii) sources are varied with sunlight
generating the primary form of vitamin D3 in the skin
and both vitamin D3 and vitamin D2 are available
through diet, making supplemental studies very difficult
to control, and iii) although studies are conducted glo-
bally, there is no worldwide consensus on key quantita-
tive measures of deficiency, insufficiency and sufficiency
of vitamin D in blood samples [1,3].
Vitamin D exists in several forms ranging from the
dietary derived D2 and photo-activated D3 analogues, al-
though a fraction of vitamin D3 also arises from the diet.
Hydroxylation in the liver affords the circulating 25-
hydroxyvitamin-D3 (25OHD3) and 25-hydroxyvitamin-
D2 (25OHD2) forms, frequently measured collectively as
25OHD. Additional metabolism in the kidney generates
the active metabolites 1-alpha,25-dihydroxyvitamin-D3,
(1α25(OH)2D3) and 1-alpha,25-dihydroxyvitamin-D2
(1α25(OH)2D2) along with the minor metabolite 24,25
(OH)2D3 [4-6]. Recent efforts have resulted in signifi-
cant improvements in the understanding of limitation and
strengths of various assays for vitamin D forms [3,7-10].
Further confounding factors arise as recent studies
have revealed the presence of the C-epimer form of
25OHD3 in adult blood samples [11], which was subse-
quently quantified in further studies [3,12,13]. The role
of vitamin D epimers is yet to be elucidated but their
presence is likely to have an associated function [14].
Given that the epimers can hamper current assays by
cross-reacting, and that they may have biological func-
tions, it is timely to develop an accurate method to ana-
lyse all forms of vitamin D, including accurate levels of
the epimers. Similar efforts to date resulted in assays
quantifying up to five analogues in various combinations
[15-18] but none included the primary forms of vitamin
D, 3-epi-25OHD2 or 1α25(OH)2D2.
This paucity of advances, despite the existence of nu-
merous reports, led us to develop a new assay for the
simultaneous analysis of eight key analogues of vitamin
D including two epimers. The aim of this paper is to re-
port the validated assay along with its application toreference samples to quantify the levels of various analo-
gues of vitamin D.
Materials and methods
Samples
Samples were obtained from the Vitamin D External
Quality Assessment Scheme (DEQAS). All the samples
are pooled sera prepared from donations from patients
undergoing therapeutic venesection for haemochroma-
tosis and occasionally polycythaemia.
Standards and reagents
All chemicals and reagents were of high purity grade.
Stanozolol-D3 (internal standard) and 7-α-hydroxy-
4-cholesten-3-one (7αC4) were obtained from LGC stan-
dards (Teddington, UK). Vitamin D3, vitamin D2,
25OHD3, 25OHD2, 1α25(OH)2D3, 1α25(OH)2D2 , 3-
epi-25OHD3, 3-epi-25OHD2, isopropanol, dichloro-
methane, methanol, hexane, deionised water, formic
acid, ammonium hydroxide, acetonitrile, ether and hex-
ane were purchased from Sigma Aldrich (Poole, UK).
Preparation of standards and samples
Methanolic stock solutions of all analytes were prepared
at a concentration of 1 mg/mL and stored in amber glass
vials at −80°C in the dark. All methanolic working solu-
tions of analytes and the internal standard were prepared
by serial dilution of stock solutions. A standard working
solution mixture of analytes and the standalone internal
standard was prepared at a concentration of 1 μg/mL.
Sample pre-treatment
Sera samples (1 mL) were thawed equilibrated at room
temperature for 15 minutes and vortex mixed. Except
for the blank, 25 μL of working solution of stanozolol-
d3 (internal standard) was added to all samples. 50 μL of
2 M formic acid were added, followed by 3 mL of iso-
propanol/methanol/ (1:1, v/v) mixture and vortex mixed
to release the protein bound analyte and to promote
protein precipitation during a 15 minutes incubation at
4°C. The resulting mixture was centrifuged at 3500 g for
5 minutes at 4°C to remove the suspended matter, with
supernatants transferred to clean amber glass tubes for
liquid-liquid extraction.
Liquid-liquid extraction (LLE)
A 3 mL dichloromethane/hexane/(1:1, v/v) mixture was
added to the remaining solution after protein precipita-
tion and the solution was vortex mixed for 1 minute and
then centrifuged at 3500 g for 5 minutes at 4°C. The
upper clear layer was transferred to a new set of glass
tubes with a further two extractions conducted on the
residual lower layer. The extracts were pooled and dried
under a gentle stream of nitrogen at room temperature
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methanol/water (1:1, v/v) solution.
LC-MS/MS procedure
A Sciex API-3000 LC-MS/MS instrument (Applied bio-
systems division of MDS health group Ltd, Canada) was
used for analysis together with an autosampler (PAL-
CTC Analytics, Switzerland), and turbomolecular pump
(1100 series, Agilent Technologies, USA). Analyst soft-
ware version 1.4.2 (AB Sciex) was used for data analyses.
A 10 μL aliquot of the sample was injected into the LC-
MS/MS system for analysis in low light conditions. An
Ultrason ES-OVM chiral column (2 mm×150 mm,
5 μm) was used in tandem with an Agilent rapid reso-
lution microbore Zorbax SB-C18 RRHD column
(2.1 mm×100 mm, 1.8 μm) with corresponding inlet fil-
ters for guarding the columns.
The column oven temperature was maintained at
40°C. However, the column switching programme was
set in a way so that the column temperature switch from
right to left after 8 minutes and then switch back to
right after 13 minutes with a temperature tolerance of
±1°C. The use of switching temperatures technique
resulted in good separation, better peak shape and re-
producibility. Various mobile phases and differing gradi-
ent compositions were explored for optimal results with
the final selected parameters as follows. Mobile phases
A consisted of acetonitrile (100%) with 0.3% (v/v) formicFigure 1 Typical chromatogram showing vitamin D analogues [1ST pe
1α25(OH)2D3-RT= 6.74; 2
nd period analytes: 7αC4-RT= 9.51, 25OHD3-
3-epi-25OHD2-RT= 11.71; 3RD period analytes: vitamin D3-RT= 14.87acid and B containing 0.1% (v/v) formic acid and ammo-
nium acetate (2 mM) with a flow rate in all steps at
0.2 mL/min. The gradient program was as follows: ini-
tial: 35% B; 0–4.0 min: a gradient change to 98% A; from
4.0–10 min: kept at 98% A; from 10–14 min: reversion
of the mobile phase to 35% B; 14.1–20.0 min; 35% B.
The mass spectrometer was auto-equilibrated for
0.5 min. The channel electron multiplier (CEM) detector
was set to 3290 eV with a deflection of 400. The mass
spectrometer parameters like deflection potential, focus-
sing potential, energy potential and collision cell exit po-
tential was optimised for each analyte. The mass
spectrometer was set to run three periods sequentially
with optimised conditions for selected analytes. The total
run time for mass spectrometer was 20 minutes. First
period was run for 8 minutes with optimum conditions
for 1α25(OH)2D3 and 1α25(OH)2D2 and stanozolol-d3
internal standard followed by second period for 5 minutes
with optimised conditions for 25OHD3, 25OHD2, 3-epi-
25OHD3, 3-epi-25OHD2 and 7αC4 and a 3rd period was
employed for a final 7 minutes for determination of vita-
min D3 and vitamin D2. The mass spectrometer was
operated in positive electrospray ionisation (ESI) mode at
an average spray voltage of 4500 V and average capillary
temperature of 450°C between the three periods. The
generated protonated molecules of all analytes were used
as precursor ions for collision activated dissociation
(CAD) into product ions in MS-MS analysis.riod analytes: Stanozolol-d3-RT= 2.96, 1α25(OH)2D2-RT = 5.49,
RT = 10.86, 3-epi-25OHD3-RT= 11.21, 25OHD2-RT= 11.46 and
and vitamin D2-RT= 15.38].
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Results from the new assay was compared to the
DEQAS mean using Bland–Altman plot to allow show-
ing discrepancies for individual samples. Coefficient of
variation (CV) was calculated as standard deviation/
mean and expressed as percentage. Data analysis was
performed using Microsoft Excel 2007.
Results and discussion
Method validation
A typical chromatogram is shown in Figure 1 illustrating
the separation of eight vitamin D analogues plus the in-
ternal standard (stanozolol-d3) and isobaric component
7-α-hydroxy-4-cholesten-3-one (7αC4) in a spiked
extracted serum sample. The calibration curves and
quality controls were prepared in vitamin d free
phosphate-buffered saline with 60 g/L human serum al-
bumin [19]. The sample pre-treatment and extractionTable 1 Validation results for vitamin D assay
Analytes in
(nmol/L)
Conctrn. QC's Linear range LOD r2
Vitamin D3 20 0.5-100 0.05 0.9997
40
80
Vitamin D2 20 0.5-100 0.05 0.9996
40
80
25OHD3 20 0.5-100 0.025 0.9999
40
80
25OHD2 20 0.5-100 0.025 0.9998
40
80
1α25(OH)2 D3 0.2 0.015-1 0.010 0.9998
0.4
0.8
1α25(OH)2 D2 0.2 0.015-1 0.010 0.9998
0.4
0.8
3-epi-25OHD3 20 0.1-100 0.05 0.9997
40
80
3-epi-25OHD2 20 0.1-100 0.05 0.9998
40
80
7αC4 20 0.5-100 0.1 0.9999
40
80method was followed with minor changes [19]. The ac-
curacy of the assay was determined as the ratio of the
compound added to the measured (mean value/nominal
value) × 100. The extraction efficiency of the com-
pounds was determined by spiking blank serum samples
prepared in human serum albumin. Absolute recoveries
were determined by comparing the concentration of the
detector response obtained from peak heights ratios of
extracted serum samples with actually added concentra-
tions of un-extracted standard response for the detector.
Relative recoveries were determined by comparing the %
of drug recovered from serum matrix against detector
response for extracted standards. Three different con-
centrations of quality controls were utilised in this assay.
To check for the assay variations for 25OHD3 and
25OHD2, a multilevel certified reference material (CRM)
serum calibrator set (Chromsystems, Germany) was also
used (based on human serum) and handled in the sameIntra-day Inter-day
Precision % CV Accuracy% Precision % CV Accuracy%
4.13 87.1 5.32 89.8
2.86 99.4 2.33 89.4
1.31 98.9 2.89 90.2
6.3 99.2 11.3 93.2
11.3 97.5 13.3 94.8
9.4 89.4 9.6 89.3
6.1 99.9 7.4 98.1
2.7 97.3 3.7 99.8
3.5 99.1 2.9 99.2
2.8 99.8 3.4 101.2
2.7 99.9 3.9 98.9
3.3 88.7 3.8 89.3
4.4 89.2 5.6 88.5
4.2 86.4 4.4 87.3
3.6 99.7 2.6 88.9
3.2 98.9 5.2 89.8
4.4 99.4 6.3 98.9
3.9 99.9 4.3 87.8
3.5 89.2 4.3 98.5
3.1 87.3 10.9 87.6
3.3 89.1 8.9 99.9
7.1 85.8 3.5 88.5
4.9 84.6 2.7 87.1
3.2 89.9 2.2 88.3
3.2 98.3 5.4 86.2
2.3 88.6 3.1 85.3
4.1 79.9 3.1 88.1
Table 2 MRM transitions of vitamin D analogues and
internal standard
Compounds Precursor Product CE
Vitamin D3 385.3 159.2 40
Vitamin D2 397.4 159.2 43
25OHD3 401.3 383.1 41
401.3 365.1 41
401.3 159.2 45
25OHD2 413.3 377.2 51
413.3 355.5 51
413.3 383.1 35
1α25(OH)2 D3 399.1 135.1 61
399.1 381.1 41
1α25(OH)2 D2 411.5 151.1 55
3-epi-25OHD3 401.3 383.1 41
401.3 365.1 41
401.3 159.2 45
3-epi-25OHD2 413.3 377.2 51
413.3 355.5 51
413.3 383.1 35
7αC4 401.3 383.1 41
401.3 365.1 41
401.3 159.2 45
Stanozolol-D3 332.2 81.2 45
Figure 2 Analytical data for DEQAS samples using the new assay. * in
only one positive sample was recorded. The error bars represent standard
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were analysed along with routine samples to meet the
standards outlined by National Institute of Standards and
Technology (NIST). External quality control samples
from the International Vitamin D External Quality As-
sessment Scheme (DEQAS) were analysed for comparison
with other participating laboratories already using LC-
MS/MS for 25OHD3 and 25OHD2 analysis.Validation results
Intra-day and inter-day precision and accuracy are
shown in Table 1. The absolute recoveries of the analytes
range from 88.2 to 97.8% and internal standard 89.6%.
Relative recoveries for analytes ranged from 89.8 to
98.2% and internal standard 89.9%. The r2 in Table 1
represents linear regression, where all the results are
presented in units of nmol/L.
Under- or over-estimation of actual 25OHD3 concen-
trations may occur owing to co-eluting epimers (e.g.
3-epi-25OHD3) and isobars (e.g. 7αC4). The endogenous
bile acid precursor 7α-hydroxy-4-cholestene-3-one
(7αC4) may cause isobaric inference in MS assays [3].
The use of high resolution microbore tandem column
technology not only chromatographically separated all
isobars and epimers from 25OHD co-eluting peaks but
also facilitated accurate and sensitive determination of
the analyte ions by sequential application of threedicates that single value is presented as no mean value is available
deviations for the 25 samples.
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cules, [M+H]+, the precursor ions and the diagnostic
product ions were monitored in the multiple reactions
monitoring (MRM) mode. The MRM parameters were
optimised for each analyte using a direct infusion of
0.1 μg/mL individual solutions and of standard com-
pounds mixture. The MRM sequence consisted of three
periods executed sequentially to monitor different tran-
sition pairs using parameters optimised for each period.
The most abundant MRM transitions for each analyte
were acquired using the conditions given in Table 2.Profiles of vitamin D analogues
The results from the pooled DEQAS samples are given
in Figure 2 revealing that all analogues were quantifiable.
As expected, the highest level was recorded for 25OHD3
with 25OHD2 present at a considerable level in all sam-
ples. The C-3 epimer of 25OHD3 and 1α25(OH)2D2
were quantified in most samples, whereas the 1α25(OH)2
D2 and 3-epi-25OHD2 were only present in one sample
(410), which contained a significant amount of endogenous
25OHD2. It should be noted, however, that these are pooled
samples from donors undergoing treatment and thus are
used for the purposes of assay comparisons.Figure 3 A: Bland-Altman plot comparing the 25OHD concentrations
of agreement. The mean difference is −5.329, the lower limit line is at −15.
concentrations obtained using the new assay and the ALTM.The Bland-Altman and correlation plots (Figure 3)
show the level of agreement and relationship between
the new method and the All Laboratory Trimmed Mean
(ALTM) data provided with the DEQAS sample. The
analytical data 25OHD for the individual samples are
presented in Figure 4 with detailed results given in
Additional file 1. As the Bland-Altman plot showed no
proportional bias (r2 = 0.0341, p = 0.376), the classic 96%
confidence interval approach was applied using the
Bland-Altman formula (mean difference ± 1.96SD) to set
the limits of agreement. Of the total 25 samples, 15 were
within the limits of agreement by Bland-Altman limit of
agreement (Figure 3A); and 18 were within the DEQAS
CV=30.0 limit (Figure 4). Generally, the 25OHD con-
centration level measures falling outside the Bland-
Altman and DEQAS limits were recorded at a lower
level than the DEQAS’ ALTM means and confidence
intervals. A strong positive relationship was evidenced be-
tween the new assay and the ALTM (r=0.72, p < 0.001).
Our data were within the limit of tolerance of the subset of
5 pooled DEQAS samples (for samples 396–400) which
were analysed by the Centers for Disease Control and Pre-
vention (Atlanta) with known 3-epi-25OHD3 levels.
Our results for the serum pools averaged −11.8% from
the overall DEQAS-ALTM for the participating laboratoriesobtained with the new assay (M1) to DEQAS. Lines represent limits
774 and the upper limit is at 5.116. B: Correlation between the 25OHD
Figure 4 Comparison of 25OHD concentration levels obtained using the new assay (blue) and ALTM (grey). Bars for new assay represent
SEM of duplicate measures. Bars on ALTM represent CV = 30.0 and denote the lower and upper limit of satisfactory performance [http://www.
deqas.org].
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cation in some samples that afforded higher concentrations
of the 25OHD. Thus, as seen in Figure 4, five results for the
new assay lie below the range of the DEQAS data (383,
401, 407, 409, 415), with two samples being above the
DEQAS (384, 397).Conclusion
In conjunction with the ability to separate 7αC4, the assay
is capable of distinguishing between every major form of
vitamin D reported to date. The results show that the new
assay’s ability to quantify 25OHD levels is comparable to
other LC-MS/MS methods represented in the DEQAS
data, thus the simultaneous measures of eight analogues
does not compromise its analytical capability for assessing
the commonly used biomarker (25OHD) for vitamin D
status. In contrast, it adds a significant capability to iden-
tify potential issues such as conversion of primary forms
to circulating or highly active forms [19]. However, the
additional capability of the new assay, namely the ability of
not only excluding but also quantifying 3-epimers of D2
and D3, along with the primary forms (D2 and D3),
1,25α(OH)2D3 and 1,25α(OH)2D2, makes this assay in-
strumental in research and clinical practice where specific
and accurate measurement of the different forms is
required.Additional file
Additional file 1: The following additional data are available with
the online version of this paper. Additional data file 1 is a table listing
the concentrations ± SEM of the 8 vitamin D forms (nmol/L) in DEQAS
pooled samples.
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